

Biocept Inc

10:56 16 Jul 2020

Biocept proposed reverse stock split endorsed by corporate advisory firms

Biocept Inc (NASDAQ:BIOC) told investors Thursday that corporate governance firms Institutional Shareholder Services (ISS) and Glass Lewis & Co have both recommended that stockholders vote in favor of the company's proposed reverse stock split.

The reverse split would reduce Biocept's total number of shares at a ratio between 1:5 and 1:30, propelling its share price above the \$1 minimum closing price requirement for continued listing on the Nasdaq.

Voting will be open through the conclusion of the company's virtual annual meeting of stockholders, which will reconvene at 1:30 PT on July 31. Stockholders can register to attend here, and the deadline to do so is 5 pm Et on July 29.

READ: Biocept wins patent in Canada to further protect Target Selector liquid biopsy test technology

The company said it has until December 7 to satisfy the requirement or it will be subject to delisting. Biocept's board of directors has also recommended stockholders vote to approve the proposal.

Shares of Biocept traded at \$0.70 Thursday morning.

ISS and Glass Lewis are independent proxy advisory firms that offer voting recommendations to pension funds, investment managers, mutual funds and other institutional shareholders.

Biocept is developing Target Selector technology, which detects and isolates cancer biomarkers such as circulating tumor cells and cell-free circulating tumor DNA. The San Diego company offers the tests commercially to doctors, hospitals, clinics and researchers, with a focus on lung, breast, gastric, colorectal and prostate cancers — which represent 45% of all metastatic cancers — as well as melanoma.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Price: 4.52

Market Cap: \$60.54 m

1 Year Share Price Graph



October 2019 April 2020 October 2020

Share Information

Code: BIOC

Listing: NASDAQ

52 week High Low
13 2.118

Sector: Medical technology & services

Website: biocept.com

Company Synopsis:

Biocept, Inc. is a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both CTCs and in plasma (ctDNA).

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).